U.s. fda approves first therapeutic indication for revance's daxxify® (daxibotulinumtoxina-lanm) for injection for the treatment of cervical dystonia

Nashville, tenn.--(business wire)--u.s. fda approves first therapeutic indication for revance's daxxify® (daxibotulinumtoxina-lanm) for injection for the treatment of cervical dystonia.

RVNC Ratings Summary

RVNC Quant Ranking